Current Research Efforts

Finally, a real solution to high cholesterol

CURRENT STAGE: Lab testing of AGXV1, AGXV2, AGXV3

Our primary focus is our set of immunotherapies designed to permanently enhance cholesterol metabolism through an immune system-mediated removal of inhibitory factors. Our proprietary multitope platform allows for a more targeted immune response to our targets, promising greater LDL and VLDL clearance than competitors. The result will be a permanent increase in LDL clearance, decreasing patients' risk of atherosclerosis and CVD, all while removing the need for expensive, long-term prescriptions to drugs that cause significant, unwanted side effects.

AGXV1 preclinical studies underway